×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: diasorin | coronavirus | testing | fda

DiaSorin Gets FDA Emergency-Use Rights for Covid-19 Test in US

DiaSorin Gets FDA Emergency-Use Rights for Covid-19 Test in US
Clinical support technician Douglas Condie extracts viruses from swab samples so that the genetic structure of a virus can be analysed and identified in the coronavirus testing laboratory at Glasgow Royal Infirmary. (Jane Barlow - WPA Pool/Getty)

Saturday, 25 April 2020 12:34 PM

DiaSorin SpA received Emergency Use Authorization from the U.S. Food and Drug Administration for a new serologic test for Covid-19.

The Liaison test is one of the first based on so-called Chemiluminescent ImmunoAssay technology to receive such authorization in the U.S., DiaSorin said Saturday in a statement. The Italian company is boosting output capacity at its Saluggia site to make several million Liaison tests in the coming months.

Earlier in April, DiaSorin said it had “CE-marked” the test, known formally as Liaison Sars-Cov-2 S1/S2 IgG, and was submitting the product to the FDA for authorization.

© Copyright 2021 Bloomberg News. All rights reserved.


Health-News
DiaSorin SpA received Emergency Use Authorization from the U.S. Food and Drug Administration for a new serologic test for Covid-19.
diasorin, coronavirus, testing, fda
95
2020-34-25
Saturday, 25 April 2020 12:34 PM
Newsmax Media, Inc.
Join the Newsmax Community
Register To Comment Login To Comment
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved